Correlation Between Blood System Impairment and Immune Index in Patients with Primary Sjögren's Syndrome
Abstract
Objective: To analyze the relationship between blood system impairment and immune indexes, including autoantibody, immunoglobulin and lip gland biopsy in patients with primary Sjogren's syndrome (pSS). Methods: The serological data of patients with Sjogren's syndrome in hospital were collected and divided into hematological system impairment group and normal group. The incidence of hematological system damage in patients with pSS and its correlation with immune indexes were analyzed. Results: 123 patients with pSS were included in this study. There were 57 patients in the blood system involvement group (46%), in which the proportions of leucopenia, anemia and thrombocytopenia were in turn; 17. 89%; 33. 3%; 4. 88%. The antibodies in the blood system affected group were abundant, and the positive rates of anti SSA and Ro-52 antibodies were significantly higher than those in the normal group. The increase of serum IgG in pSS patients accounted for nearly 50%; The levels of serum IgG and complement C3 were significantly different from those in the control group. The positive rate of lip gland biopsy in pSS patients was more than 90%, and there was no significant difference between the two groups. Conclusion: Hematological system involvement was common in PSS patients. The positive rates of anti SSA and Ro-52 antibodies increased significantly, the level of IgG increased and the level of complement C3 decreased; However, there was no significant difference in blood system involvement between high IgG and low IgG groups; The positive rate of lip gland biopsy in PSS patients was more than 90%.
References
[2] Zhao Y, et al, Primary Sjögren syndrome in Han Chinese: clinical and immunological characteristics of 483 patients. Medicine, 2015. 94(16).
[3] Vitali C, et al, Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis, 2002. 61(6): p. 554-8.
[4] Nishishinya MB, et al, Identification of lymphoma predictors in patients with primary Sjogren's syndrome: a systematic literature review and meta-analysis. Rheumatol Int, 2015. 35(1): p. 17-26.
[5] Fu R, Shao ZH, Hong LH, Jia HR, Bone marrow B lymphocytes and apoptosis-related protein levels in patients with immune-related pancytopenia. Chinese Journal of Hematology, 2002 (05): p. 11-13.
[6] Brito-Zeron P, et al, Prevalence and clinical relevance of autoimmune neutropenia in patients with primary Sjogren's syndrome. Semin Arthritis Rheum, 2009. 38(5): p. 389-95.
[7] Zhang YL, et al, primary Sjogren's syndrome in 103 patients with hematological changes. Journal of Clinical Internal Medicine, 2001 (01): p. 55-56.
[8] Cheng YJ, et al. , studied the gene expression of peripheral blood mononuclear cells in Sjogren's syndrome patients. Chinese Journal of Rheumatology, 2009. 13 (4): p. 240-243.
[9] Namkoong E, et al., Effect of anti-muscarinic autoantibodies on leukocyte function in Sjogren's syndrome. Mol Immunol, 2017. 90: p. 136-142.
[10] Baldini, C. , et al. , Primary Sjogren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology (Oxford), 2014. 53(5): p. 839-44.
[11] Wang J, Xuan L and Dong ZH, Study situation of primary Sjogren's syndrome combined with blood system damage. Journal of Medical Research, 2015. 44 (3): p. 169-171.
[12] Sun Y, A retrospective study of the clinical characteristics of patients with primary Sjogren's syndrome complicated with hyperimmunoglobulinemia. 2020, Inner Mongolia Medical University. P, 48.
[13] Seror R, et al, EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis, 2010. 69(6): p. 1103-9.
Copyright (c) 2022 Meilv Yang
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.
